NIH Deploys Picodya’s IVD Platform to Detect Global Viral Threats
Picodya, the creator of a hybrid IVD solution for multiplexed POC testing, announced the deployment of its B-Matrix technology in NIH labs.
Read MorePosted by Andy Lundin | Jan 9, 2024 | Diagnostic Technologies |
Picodya, the creator of a hybrid IVD solution for multiplexed POC testing, announced the deployment of its B-Matrix technology in NIH labs.
Read MorePosted by Andy Lundin | Jan 2, 2024 | Covid 19 |
An artificial intelligence (AI) model can predict which COVID variants are likely to cause new waves of infection.
Read MorePosted by Andy Lundin | Dec 14, 2023 | Mass Spectrometry |
The technique doesn’t require long-term bacterial sample prep and expensive reagents, making it promising for studying bacteria strains.
Read MorePosted by Andy Lundin | Nov 28, 2023 | Sexually Transmitted Diseases |
HIV can hide in the body for many years before symptoms appear. Meanwhile, it is quietly killing part of the immune system.
Read MorePosted by Chris Wolski | Nov 24, 2023 | Tuberculosis |
Though without a standard TB diagnosis, guidelines recommend the use of either the TST or IGRAs to test for latent tuberculosis infections.
Read More